Round Tables
On Thursday 17 June and Friday 18 June 2010 (07:15-08:15), there will be the following Roundtable sessions. Delegates can select the Roundtable(s) of their choice as part of the registration system.
|
Categories |
Thursday 17 June |
Friday 18 June |
| Pulmonology | Title: Diagnosis and Treatment of Pulmonary Hypertension Leader: A. Román (ES) |
Title: Measuring and Improving CF Centre Care Leader: E. Riestschel, DE Objective: The objective of this roundtable is to discuss the application of quality improvement principles in CF Centres. In particular we will discuss the "5 P´s" - purpose, patients, professionals, process, pattern- as well as outcome parameters for benchmarking. |
| Title: Sleep Medicine in CF-Normal and Dysfunctional Sleep - Assessment and Treatment Leader: B. Fauroux, FR Objective: The objective of this roundtable is to discuss sleep disordered breathing in patients with cystic fibrosis. In particular we will discuss nocturnal alveolar hypoventilation, and when, how and where to perform a sleep study, and the practical management of nocturnal hypoventilation in these patients. |
Title: Proteases and Anti-proteases Leader: C. Taggart, UK Objective: The objective of this roundtable is to describe and discuss the role of proteases and antiproteases in the CF lung. Discussion will also focus on the use of protease inhibitors for the treatment of CF lung disease and the possibilities and problems associated with this therapeutic approach. |
|
|
Title: Treatment of MOTT (Mycobacteria Other Than Tuberculosis) |
Title: Use of New Antibiotics in CF Leader: M. Parkins, CA Objective: The objective of this round table is to discuss the role of antibacterial agents recently approved or currently under clinical investigation for use in CF. In particular, we will focus on parenteral agents for mangement of pulmonary exacerbations and aerosolized therapy in the chronic maintenance of lung health. |
|
| Microbiology | Title: Anaerobes - Pathogens in CF? Leader: D. Worlitzsch, DE Objective: The objective of this roundtable is to discuss the contribution of facultative and obligate anaerobic bacteria to the pathogenesis of infection and inflammation in the CF lung. |
Title: Molecular Identification Methods Leader: P. Dřevinek, CZ Objective: Correct identification of many emerging CF pathogens is dependent on the use of molecular methods. With special attention to identification of Burkholderia cepacia complex bacteria, we will discuss pros/cons of molecular genetic approach and methods that are currently available. |
| Title: Preventing Acquisition of CF Pathogens from the Environment Leader: M. Denton, UK Objective: The objective of this round table will be to discuss the evidence that some CF pathogens are acquired from the environment and the future development of realistic strategies to prevent such acquisition. |
Title: MRSA - A Pathogen in CF? Leader: R. Cantón, ES Objective: To discuss current information of MRSA epidemiology and the potential influence of different clones in pulmonary function on cystic fibrosis patients as well as different therapeutic options to avoid pathogenic colonization. |
|
| Genetics/Screening & Diagnosis |
Title: Bioinformatic Tools |
Title: Designing Mutation Panels for NBS and Carrier Testing Leader: C. Castellani, IT Objective: The objective of this roundtable is to discuss criteria for inclusion of mutations in panels for neonatal screening and carrier testing. The discussion will not focus on technical issues, but on disease liability of mutations. |
| Title: NBS: What to do after a borderline ST? Leader: K. Southern, UK Objective: A borderline sweat test result after newborn screening for CF presents a difficult clinical dilemma. Case scenarios will be used to illustrate the management of these infants with reference to recently published guidelines. |
Title: Next Generation Sequencing Leader: H. Cuppens, BE Objective: The objective of this roundtable is to discuss the ongoing revolution of next-generation sequencing. In particular we will discuss how one should deal with these data if implemented for CFTR mutation testing and screening. |
|
| CFTR/Cell |
Title: CFTR Endocytosis and Recycling |
Title: Alternative Chloride Channels Leader: L. J. Galietta, IT Objective: The objective of the roundtable is to discuss the molecular identity and the physiological role of other epithelial chloride channels different from CFTR. Such channels may represent alternative therapeutic targets to stimulate chloride transport in CF. |
| Title: Monitoring CFTR Function in Clinical Trials Leader: I. Sermet, FR |
Title: ENaC and ASL Therapies Leader: M. Mall, DE Objective: The objective of this roundtable is to discuss the role of ENaC and ASL depletion in the pathogenesis and as a therapeutic target in CF lung disease. |
|
| Title: Mechanism of action for CFTR correctors and potentiators Leader: H. De Jonge, NL Objective: The most recent information about the targets and mechanism of action of deltaF508CFTR correctors and potentiators will be evaluated and discussed, with emphasis on the distinction between CFTR-specific and non-specific mechanisms |
||
| GI / Liver / Endo / Nutrition |
Title: Bone Health in CF Leader: L. Hjelte, SE |
Title: Body Image and Behaviour Leader: S. Perobelli, IT Objective: The objective of this roundtable is to discuss the influence of body image on the patient's self-managment and compliance, particularly in following nutritional recommendations. |
| Title: Management of Cystic Fibrosis Related Diabetes Leader: A. Morton, UK Objective: The objective of this round table is to discuss the medical and dietary management of Cystic Fibrosis Related Diabetes. We will discuss when insulin therapy should be introduced including looking at the evidence for early intervention, changes in dietary therapy and reactive hypoglycaemia |
Title: Nutritional Management Pre- and Post-Transplant Leader: D. Kalnins, CA Objective: The objectives for this roundtable are: to identify and discuss the strategies to maintain good nutritional status and to describe nutritional issues and their management pre and post lung transplant |
|
| Clinical Trials/ New Therapies |
Title: Clinical Trial Design Leader: H. Tiddens, NL |
Title: From Systematic Review to Clinical Trial Leader: A. Smyth, UK Objective: This round table will allow participants to discuss, with examples, key aspects of clinical care in CF where there is insufficient evidence to guide practice. The role of systematic reviews will be discussed, in summarising the available evidence, exposing gaps and acting as a stimulus to clinical trials. |
| Title: ECFS CTN - What is going on? Leader: V. Bulteel, BE Objective: This session will allow participants to learn more about the objectives and specific activities of the European Clinical Trials Network |
Title: Outcome Measures for Clinical Trials Leader: C. De Boeck, BE |
|
| Title: Practicalities of running an ECFS Clinical Trial Centre Leader: T. Lee, UK Objective: This session will be an opportunity for those already involved in ECFS Clinical Trial Network (CTN), as well as those from CF centers who may consider bidding to become part of the ECFS CTN in the future. We will discuss key practical issues such as logistics, recruitment, documentation, and staff involvement, as well as focussing on the benefits of involvement for both the people with CF and the staff at your center. |
||
| Epidemiology/ Registry |
Title: Specific Genetics of CFTR in European Minorities Leader: M. Macek, CZ Objective: The objective of this roundtable is to discuss current approaches to customisation of panels of CF causing mutations in European minorities and/or immigrants for achieving the highest possible mutation detection rate in CF DNA diagnostics. |
Title: Definition and Documentation of Exacerbations Leader: T. Pressler, DK |
| Title: The European CF Registry Leader: H. Olesen, DK Objective: The objective of this roundtable is to discuss improvement and upgrading of variables collected in the European CF Registry, and to discuss means of using the data for quality improvement and research. |
||
| Nursing/ Psychosocial |
Title: Assisted Conception Leader: V. Hall, UK Objective: The objective of this roundtable is to discuss methods of assisted conception and the practical, moral and ethical considerations associated with such treatment. |
Title: Interventions for Anxiety and Depression Leader: L. Goldbeck, DE Objective: The objective of this roundtable is to discuss clinically relevant symptoms of anxiety and or depression in patients with CF and their caregivers and about the interference of anxiety/depression with treatment of CF, how to address these symptoms, and how to plan psychological/psychiatric interventions adapted to symptom severity, individual preferences of the patient, and availability. The input of case examples is welcome. |
| Title: Defining a Pulmonary Exacertbation: Patient Perspectives Leader: J. Abbott, UK Objective: The objective of this roundtable is to identify and discuss patient-reported indicators of a pulmonary exacerbation. Discussion will focus on both children and adults and the complexity and severity of CF disease. |
Title: Managing Parenthood in CF Leader: K. Colpaert, BE Objective: The objective of this round table is to discuss how patients experience parenthood while caring for their CF and how we can better inform patients with a wish for a child about parenting and its consequences. |
|
| Title: Well Siblings Leader: T. Havermans, BE Objective: In this roundtable we will be discussing the impact of CF on siblings, their adjustment and resilience and their role within the family with CF. |
||
| Physiotherapy | Title: Gastro-oesophageal Reflux Leader: B. Button, AUS Objective: The objective of this round table is to discuss symptomatic and silent gastro-oesophageal reflux. Some physiotherapy techniques, positions and exercises are more inclined to exacerbate the problem. We will discuss what is known about GOR together with ways to minimize the problem during physiotherapy |
Title: IPV Leader: F. Van Ginderdeuren, BE Objective: The objective of this roundtable is to discuss the different indications for use of IPV in CF. We will discuss different strategies for use of IPV in infants and adults with CF |
|
Title: Physiotherapy Care of the Complex Patient |
Title: Physiotherapy in infants |
|
| AHP |
Title: CF Clinical Pharmacists |
Title: CF Research Coordinators Leader: T. Pugatsch, IL Objective: Site management for Research Coordinators: the do's, don’ts and how to survive |
| Title: How to Prepare and Write an Abstract for Conference submission Leader: A. Quittner, US |
Title: How to Refine a Research Idea into a Research Question |
Printer-friendly version